Prediction of Adverse Cardiovascular Events of Noncardiovascular Drugs through Drug-Target Interaction Networks

摘要

Several postmarketing studies of adverse cardiac eff ectsof noncardiovascular drugs have been reported over the pastdecade. Th is has included rosiglitazone, an antidiabetic drug.Demonstration of serious complications has been traditionallybased on systematic reviews and meta-analyses of clinicaltrials. However, there is a need to develop new tools to enablethe prediction of adverse drug eff ects in both early discoveryand postmarketing stages of drug development. Th is can beaccomplished through drug-target interactions at a systemslevel.